These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 33833512)

  • 1. Nucleolin-Targeting AS1411 Aptamer-Modified Micelle for the Co-Delivery of Doxorubicin and miR-519c to Improve the Therapeutic Efficacy in Hepatocellular Carcinoma Treatment.
    Liang X; Wang Y; Shi H; Dong M; Han H; Li Q
    Int J Nanomedicine; 2021; 16():2569-2584. PubMed ID: 33833512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modified AS1411 Aptamer Suppresses Hepatocellular Carcinoma by Up-Regulating Galectin-14.
    Cho Y; Lee YB; Lee JH; Lee DH; Cho EJ; Yu SJ; Kim YJ; Kim JI; Im JH; Lee JH; Oh EJ; Yoon JH
    PLoS One; 2016; 11(8):e0160822. PubMed ID: 27494117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Innovative gelatin-based micelles with AS1411 aptamer targeting and reduction responsiveness for doxorubicin delivery in tumor therapy.
    Yu J; Zhang Y; Xu M; Jiang D; Liu W; Jin H; Chen P; Xu J; Zhang L
    Biomed Pharmacother; 2024 May; 174():116446. PubMed ID: 38513599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell Surface Nucleolin as a Promising Receptor for Effective AS1411 Aptamer-Mediated Targeted Drug Delivery into Cancer Cells.
    Mosafer J; Mokhtarzadeh A
    Curr Drug Deliv; 2018; 15(9):1323-1329. PubMed ID: 30039760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aptamer-Aptamer Chimera for Targeted Delivery and ATP-Responsive Release of Doxorubicin into Cancer Cells.
    Esawi E; Alshaer W; Mahmoud IS; Alqudah DA; Azab B; Awidi A
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOXM1 Aptamer-Polyethylenimine Nanoplatform Coated With Hyaluronic Acid And AS1411 Aptamer For Dual-Targeted Delivery of Doxorubicin And Synergistic Treatment of Tumor Cells.
    Khademi Z; Yazdi KS; Ramezani M; Alibolandi M; Rezvani SA; Abnous K; Taghdisi SM
    J Pharm Sci; 2024 Aug; 113(8):2198-2207. PubMed ID: 38432623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An AS1411 aptamer-conjugated liposomal system containing a bubble-generating agent for tumor-specific chemotherapy that overcomes multidrug resistance.
    Liao ZX; Chuang EY; Lin CC; Ho YC; Lin KJ; Cheng PY; Chen KJ; Wei HJ; Sung HW
    J Control Release; 2015 Jun; 208():42-51. PubMed ID: 25637705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel polymer micelle mediated co-delivery of doxorubicin and P-glycoprotein siRNA for reversal of multidrug resistance and synergistic tumor therapy.
    Zhang CG; Zhu WJ; Liu Y; Yuan ZQ; Yang SD; Chen WL; Li JZ; Zhou XF; Liu C; Zhang XN
    Sci Rep; 2016 Mar; 6():23859. PubMed ID: 27030638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic efficacy and cardioprotection of nucleolin-targeted doxorubicin-loaded ultrasound nanobubbles in treating triple-negative breast cancer.
    Fang K; Wang L; Huang H; Dong S; Guo Y
    Nanotechnology; 2021 Mar; 32(24):. PubMed ID: 33690196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted co-delivery of FOXM1 aptamer and DOX by nucleolin aptamer-functionalized pH-responsive biocompatible nanodelivery system to enhance therapeutic efficacy against breast cancer: in vitro and in vivo.
    Masoudi M; Taghdisi SM; Hashemitabar G; Abnous K
    Drug Deliv Transl Res; 2024 Jun; 14(6):1535-1550. PubMed ID: 38161196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NIR-cleavable drug adducts of gold nanostars for overcoming multidrug-resistant tumors.
    Del Valle AC; Su CK; Sun YC; Huang YF
    Biomater Sci; 2020 Mar; 8(7):1934-1950. PubMed ID: 32039412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nucleolin-Targeting AS1411-Aptamer-Modified Graft Polymeric Micelle with Dual pH/Redox Sensitivity Designed To Enhance Tumor Therapy through the Codelivery of Doxorubicin/TLR4 siRNA and Suppression of Invasion.
    Yang S; Ren Z; Chen M; Wang Y; You B; Chen W; Qu C; Liu Y; Zhang X
    Mol Pharm; 2018 Jan; 15(1):314-325. PubMed ID: 29250957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-383 inhibits doxorubicin resistance in hepatocellular carcinoma by targeting eukaryotic translation initiation factor 5A2.
    Tu C; Chen W; Wang S; Tan W; Guo J; Shao C; Wang W
    J Cell Mol Med; 2019 Nov; 23(11):7190-7199. PubMed ID: 30801960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delivery of miR-375 and doxorubicin hydrochloride by lipid-coated hollow mesoporous silica nanoparticles to overcome multiple drug resistance in hepatocellular carcinoma.
    Xue H; Yu Z; Liu Y; Yuan W; Yang T; You J; He X; Lee RJ; Li L; Xu C
    Int J Nanomedicine; 2017; 12():5271-5287. PubMed ID: 28769563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis of multimodal polymersomes for targeted drug delivery and MR/fluorescence imaging in metastatic breast cancer model.
    Zavvar T; Babaei M; Abnous K; Taghdisi SM; Nekooei S; Ramezani M; Alibolandi M
    Int J Pharm; 2020 Mar; 578():119091. PubMed ID: 32007591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multifunctional hybrid micelles with tunable active targeting and acid/phosphatase-stimulated drug release for enhanced tumor suppression.
    Liu X; Li Y; Tan X; Rao R; Ren Y; Liu L; Yang X; Liu W
    Biomaterials; 2018 Mar; 157():136-148. PubMed ID: 29268144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RNA aptamer-conjugated liposome as an efficient anticancer drug delivery vehicle targeting cancer cells in vivo.
    Baek SE; Lee KH; Park YS; Oh DK; Oh S; Kim KS; Kim DE
    J Control Release; 2014 Dec; 196():234-42. PubMed ID: 25450401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional Doxorubicin-Loaded Omega-3 Unsaturated Fatty Acids Nanoparticles in Reversing Hepatocellular Carcinoma Multidrug Resistance.
    Wang C; Wei X; Shao G
    Med Sci Monit; 2021 Feb; 27():e927727. PubMed ID: 33524008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-101 and doxorubicin codelivered by liposomes suppressing malignant properties of hepatocellular carcinoma.
    Xu F; Liao JZ; Xiang GY; Zhao PX; Ye F; Zhao Q; He XX
    Cancer Med; 2017 Mar; 6(3):651-661. PubMed ID: 28135055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extracellular vesicles: Natural liver-accumulating drug delivery vehicles for the treatment of liver diseases.
    Zhang G; Huang X; Xiu H; Sun Y; Chen J; Cheng G; Song Z; Peng Y; Shen Y; Wang J; Cai Z
    J Extracell Vesicles; 2020 Dec; 10(2):e12030. PubMed ID: 33335695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.